You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
As part of a May 13, 2015 meeting of the Biologic Advisory Committee: Blood Products, the committee will hear an update on FDA considerations for a revised blood donor deferral policy for men who have sex with men.
The complete agenda for the meeting, scheduled from 8:00 am to 5:30 pm:
Committee will meet in open session to discuss strategies for implementation of serological and nucleic acid testing for Babesia microtiin blood donors. In the afternoon, the committee will hear update presentations on the following topics: 1) FDA considerations for Hemoglobin S Testing in blood donors; and 2) FDA considerations for a revised blood donor deferral policy for men who have sex with men. Following the update presentations, the committee will hear presentations on the research programs of the Laboratory of Cellular Hematology, Division of Hematology Research and Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA.
Location:
The meeting will be conducted at the FDA White Oak Campus, located at 10903 New Hampshire Avenue., Building 31 Conference Center, The Great Room, room 1503. Silver Spring, MD 20993-0002, as well as being web cast (see below).
Materials for this meeting will be available 2 days prior to the meeting date at the Blood Products Advisory Committee Meeting main page.
Public Participation Information
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
- Written submissions may be made to the contact person on or before May 6, 2015
- Oral presentations on May 13, 2015 from the public will be scheduled between approximately 11:15 a.m. and 12:15 p.m. and 4:30 p.m. and 5:00 p.m. (for information e-mail: Bryan.Emery@xxxxxxxxxxx or email: Joanne.Lipkind@xxxxxxxxxxx)
- For those unable to attend in person, the meeting will also be web cast. The Web cast will be available at the following link.
Blood Products Advisory Committee meeting May 13, 2015: https://collaboration.fda.gov/bpac2015/
Contact Information
- Bryan Emery or Joanne Lipkind
10903 New Hampshire Ave.,
Bldg. 71, rm. 6132,
Silver Spring, MD 20993-0002,
240-402-8054
e-mail: Bryan.Emery@xxxxxxxxxxx or email: Joanne.Lipkind@xxxxxxxxxxx
- Please call the FDA Advisory Committee Information Line for up-to-date information on this meeting.
1-800-741-8138 (301-443-0572 in the Washington, DC, area).
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Bryan Emery or Joanne Lipkind at least 7 days in advance of the meeting.
The meetings are free and open to the public, with no prior registration. Attendees must have a valid photo ID. Parking is available on site.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for procedures on public conduct during advisory committee meetings.
Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration
Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
